Earnings ·
Inovio Pharmaceuticals reported a net loss of $6.0 million ($0.07 per share) for the quarter ended June 30, 2026…
INOInovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals reported a net loss of $6.0 million ($0.07 per share) for the quarter ended June 30, 2026, compared to a $23.5 million loss in the prior year period, driven by a $13.9 million non-cash gain on warrant liabilities. Operating expenses decreased to $18.6 million from $23.1 million as R&D and G&A costs declined. The company raised approximately $18.3 million net proceeds from an underwritten public equity offering in July 2026, bringing total cash resources to $36.7 million at quarter-end. Regulatory progress includes the FDA review of the BLA for INO-3107 targeting a PDUFA date of October 30, 2026, and positive Phase 3 results for partner VGX-3100 in China. The company anticipates its current cash position will fund operations into late Q1 2027. Inovio Pharmaceuticals is a biotechnology company focused on developing and commercializing DNA medicines to treat HPV-related diseases, cancer, and infectious diseases.